VRCA Quote, Financials, Valuation and Earnings

Corcept Therapeutics has a net margin of -283.28% compared to Verrica Pharmaceuticals's net margin of 13.07%. Verrica Pharmaceuticals's return on equity of -2619.46% beat Corcept Therapeutics's return on equity of 21.3%.

Verrica Pharmaceuticals has a consensus price target of $3.33, signalling upside risk potential of 481.84%. On the other hand Corcept Therapeutics has an analysts' consensus of $138.25 which suggests that it could grow by 79.99%. Given that Verrica Pharmaceuticals has higher upside potential than Corcept Therapeutics, analysts believe Verrica Pharmaceuticals is more attractive than Corcept Therapeutics.

Verrica Pharmaceuticals has a beta of 1.730, which suggesting that the stock is 73.03% more volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.215, suggesting its less volatile than the S&P 500 by 78.473%.

Verrica Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verrica Pharmaceuticals pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.

Verrica Pharmaceuticals quarterly revenues are $3.4M, which are smaller than Corcept Therapeutics quarterly revenues of $157.2M. Verrica Pharmaceuticals's net income of -$9.7M is lower than Corcept Therapeutics's net income of $20.5M. Notably, Verrica Pharmaceuticals's price-to-earnings ratio is -- while Corcept Therapeutics's PE ratio is 66.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verrica Pharmaceuticals is 5.10x versus 13.00x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Edgewise Therapeutics has a net margin of -283.28% compared to Verrica Pharmaceuticals's net margin of --. Verrica Pharmaceuticals's return on equity of -2619.46% beat Edgewise Therapeutics's return on equity of --.

Verrica Pharmaceuticals has a consensus price target of $3.33, signalling upside risk potential of 481.84%. On the other hand Edgewise Therapeutics has an analysts' consensus of $39.00 which suggests that it could grow by 172.25%. Given that Verrica Pharmaceuticals has higher upside potential than Edgewise Therapeutics, analysts believe Verrica Pharmaceuticals is more attractive than Edgewise Therapeutics.

Verrica Pharmaceuticals has a beta of 1.730, which suggesting that the stock is 73.03% more volatile than S&P 500. In comparison Edgewise Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Verrica Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verrica Pharmaceuticals pays -- of its earnings as a dividend. Edgewise Therapeutics pays out -- of its earnings as a dividend.

Verrica Pharmaceuticals quarterly revenues are $3.4M, which are larger than Edgewise Therapeutics quarterly revenues of --. Verrica Pharmaceuticals's net income of -$9.7M is higher than Edgewise Therapeutics's net income of -$40.8M. Notably, Verrica Pharmaceuticals's price-to-earnings ratio is -- while Edgewise Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verrica Pharmaceuticals is 5.10x versus -- for Edgewise Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

RxSight has a net margin of -283.28% compared to Verrica Pharmaceuticals's net margin of -21.61%. Verrica Pharmaceuticals's return on equity of -2619.46% beat RxSight's return on equity of -10.39%.

Verrica Pharmaceuticals has a consensus price target of $3.33, signalling upside risk potential of 481.84%. On the other hand RxSight has an analysts' consensus of $21.18 which suggests that it could grow by 32.3%. Given that Verrica Pharmaceuticals has higher upside potential than RxSight, analysts believe Verrica Pharmaceuticals is more attractive than RxSight.

Verrica Pharmaceuticals has a beta of 1.730, which suggesting that the stock is 73.03% more volatile than S&P 500. In comparison RxSight has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Verrica Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. RxSight offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verrica Pharmaceuticals pays -- of its earnings as a dividend. RxSight pays out -- of its earnings as a dividend.

Verrica Pharmaceuticals quarterly revenues are $3.4M, which are smaller than RxSight quarterly revenues of $37.9M. Verrica Pharmaceuticals's net income of -$9.7M is lower than RxSight's net income of -$8.2M. Notably, Verrica Pharmaceuticals's price-to-earnings ratio is -- while RxSight's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verrica Pharmaceuticals is 5.10x versus 4.29x for RxSight. Usually stocks with elevated PS ratios are considered overvalued.

Xeris Biopharma Holdings has a net margin of -283.28% compared to Verrica Pharmaceuticals's net margin of -15.34%. Verrica Pharmaceuticals's return on equity of -2619.46% beat Xeris Biopharma Holdings's return on equity of -1019.2%.

Verrica Pharmaceuticals has a consensus price target of $3.33, signalling upside risk potential of 481.84%. On the other hand Xeris Biopharma Holdings has an analysts' consensus of $6.10 which suggests that it could grow by 26.29%. Given that Verrica Pharmaceuticals has higher upside potential than Xeris Biopharma Holdings, analysts believe Verrica Pharmaceuticals is more attractive than Xeris Biopharma Holdings.

Verrica Pharmaceuticals has a beta of 1.730, which suggesting that the stock is 73.03% more volatile than S&P 500. In comparison Xeris Biopharma Holdings has a beta of 0.926, suggesting its less volatile than the S&P 500 by 7.36%.

Verrica Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xeris Biopharma Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verrica Pharmaceuticals pays -- of its earnings as a dividend. Xeris Biopharma Holdings pays out -- of its earnings as a dividend.

Verrica Pharmaceuticals quarterly revenues are $3.4M, which are smaller than Xeris Biopharma Holdings quarterly revenues of $60.1M. Verrica Pharmaceuticals's net income of -$9.7M is lower than Xeris Biopharma Holdings's net income of -$9.2M. Notably, Verrica Pharmaceuticals's price-to-earnings ratio is -- while Xeris Biopharma Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verrica Pharmaceuticals is 5.10x versus 3.25x for Xeris Biopharma Holdings. Usually stocks with elevated PS ratios are considered overvalued.